Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/24758
Full metadata record
DC FieldValueLanguage
dc.contributor.authorManca, R-
dc.contributor.authorPardiñas, AF-
dc.contributor.authorVenneri, A-
dc.date.accessioned2022-06-30T14:39:35Z-
dc.date.available2022-06-30T14:39:35Z-
dc.date.issued2022-06-21-
dc.identifierORCID iD: Riccardo Manca https://orcid.org/0000-0003-1715-6442-
dc.identifierORCID iD: Annalena Venneri https://orcid.org/0000-0002-9488-2301-
dc.identifier.citationManca, R., Pardiñas, A.F. and Venneri, A. for the Alzheimer’s Disease Neuroimaging Initiative (2022) 'The neural signatures of psychoses in Alzheimer’s disease: a neuroimaging genetics approach', European Archives of Psychiatry and Clinical Neuroscience, 273 (1), pp. 253 - 267, doi: 10.1007/s00406-022-01432-6.en_US
dc.identifier.issn0940-1334-
dc.identifier.urihttps://bura.brunel.ac.uk/handle/2438/24758-
dc.descriptionData availability: All ADNI data are made publicly available.en_US
dc.description.abstractCopyright © The Author(s) 2022. Psychoses in Alzheimer’s disease (AD) are associated with worse prognosis. Genetic vulnerability for schizophrenia (SCZ) may drive AD-related psychoses, yet its impact on brain constituents is still unknown. This study aimed to investigate the association between polygenic risk scores (PRSs) for SCZ and psychotic experiences (PE) and grey matter (GM) volume in patients with AD with (AD-PS) and without (AD-NP) psychosis. Clinical, genetic and T1-weighted MRI data for 800 participants were extracted from the ADNI database: 203 healthy controls, 121 AD-PS and 476 AD-NP. PRSs were calculated using a Bayesian approach and analysed at ten p-value thresholds. Standard voxel-based morphometry was used to process MRI data. Logistic regression models including both PRSs for SCZ and PE, and an AD-PRS were used to predict psychosis in AD. Associations between PRSs and GM volume were investigated in the whole sample and the three groups independently. Only the AD-PRS predicted psychosis in AD. Inconsistent associations between the SCZ-PRS and PE-PRS and GM volumes were found across groups. The SCZ-PRS was negatively associated with medio-temporal/subcortical volumes and positively with medial/orbitofrontal volumes in the AD-PS group. Only medio-temporal areas were more atrophic in the AD-PS group, while there was no significant correlation between psychosis severity and GM volume. Although not associated with psychoses, the SCZ-PRS was correlated with smaller medio-temporal and larger orbitofrontal volumes in AD-PS. Similar alterations have also been observed in SCZ patients. This finding suggest a possible disconnection between these regions associated with psychoses in more advanced AD.en_US
dc.description.sponsorshipAlzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California.-
dc.format.extent253 - 267-
dc.format.mediumPrint-Electronic-
dc.languageEnglish-
dc.language.isoenen_US
dc.publisherSpringer Natureen_US
dc.rightsCopyright © The Author(s) 2022. Rights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.subjectpolygenic risken_US
dc.subjectneuropsychiatricen_US
dc.subjectdementiaen_US
dc.subjectschizophreniaen_US
dc.subjectdisconnectionen_US
dc.subjectorbitofrontalen_US
dc.titleThe neural signatures of psychoses in Alzheimer’s disease: a neuroimaging genetics approachen_US
dc.typeArticleen_US
dc.identifier.doihttps://doi.org/10.1007/s00406-022-01432-6-
dc.relation.isPartOfEuropean Archives of Psychiatry and Clinical Neuroscience-
pubs.issue1-
pubs.publication-statusPublished-
pubs.volume273-
dc.identifier.eissn1433-8491-
dc.rights.holderThe Author(s)-
Appears in Collections:Dept of Life Sciences Research Papers

Files in This Item:
File Description SizeFormat 
FullText.pdfCopyright © The Author(s) 2022. Rights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.3.06 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons